How to buy shares of Blueprint Medicines (BPMC) | Explained

blueprint medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for people with cancer and blood disorders, and multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy in the United States and Europe. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, a potent orally available KIT inhibitor for the treatment of non-advanced MS and other mast cell disorders; and fisogatinib, a potent orally available inhibitor, which is in phase 1b/2 trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib for the treatment of RET-altered non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma and other solid tumors; BLU-701 and BLU-945, investigational potent and selective inhibitors of double mutant EGFR that are in preclinical stage for patients with EGFR-induced NSCLC. In addition, the company is developing BLU-782, an investigational oral activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressiva. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was previously known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts. that are in the preclinical stage for patients with EGFR-induced NSCLC. In addition, the company is developing BLU-782, an investigational oral activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressiva. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was previously known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Mass. that are in the preclinical stage for patients with EGFR-induced NSCLC. In addition, the company is developing BLU-782, an investigational oral activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressiva. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was previously known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Mass. which is in phase I clinical trials for the treatment of fibrodysplasia ossificans progressiva. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was previously known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Mass. which is in phase I clinical trials for the treatment of fibrodysplasia ossificans progressiva. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was previously known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011.

How to buy shares of Blueprint Medicines (BPMC) | Explained

Do you want to buy Blueprint Medicines (BPMC) shares on Nasdaq safely and using a regulated broker in Europe? Does it strike you to be able to make your profits profitable each month and extract interest on the stock market? Here I am going to show you how you can register with DEGIRO , a reliable and low-fee German investment bank, and how you can get your first share of Blueprint Medicines Corporation (BPMC) (BPMC) quickly and easily.

What we will do is easy to carry out :

  • First we will register in Degiro, a platform where we are going to buy shares of Blueprint Medicines Corporation (BPMC), (BPMC).
  • In this step we will add funds and thus be able to make our 1st investment.
  • When we have the funds, what we will do is search for Blueprint Medicines using the ticker, in this case it is BPMC.
  • To finish we will only add the number of shares that we will buy, value and the type of order.

The summary may have been a bit basic for you, so I am going to summarize the procedure with images:

How to start investing in degiro.

As a first step we must register in degiro through the following link :

buy shares of Blueprint Medicines Corporation (BPMC)

It will ask us for an email, a username and a password to enter, and then we must continue using the link that they have sent us by mail.

Next, DEGIRO will require information of interest in order to accept our document . We must have at hand the passport, DNI (identity document) or driving license, your cell phone and the bank account number that we are going to place to proceed to make our first deposit in IBAN format. If you don’t know what this format is, you can check this simple tutorial we wrote .

stock Blueprint Medicines

Once our account is credited, we can enter money from the Deposit/Withdraw option. We have the possibility of making a bank transfer that will take between 1 to 2 days, or to be able to make the deposit instantly thanks to Sofort, a totally secure and reliable payment gateway.

bank transfer Blueprint Medicines

How to buy shares of Blueprint Medicines (BPMC) through DeGiro

The moment we have the capital we will have the possibility of getting our 1st share. You can press the Place Order button in the corner or use the spin finder and type in the ticker. In the following image you will find that I have written the Amazon Ticker but you must enter (BPMC), the Blueprint Medicines ticker. As we are talking about an action, we will detect that the related businesses and companies are listed and there we will discover to find Blueprint Medicines. The most fundamental thing is that the ticker, the name of the company and the market in which it is listed coincide. Amazon is listed on NASDAQ (NDQ) and in your case Blueprint Medicines Corporation (BPMC) is listed on Nasdaq. This step is very essential so do not make a mistake.

american stock market this week Blueprint Medicines

At the moment of placing the order, we are going to pay special attention to what I am going to explain to you . We have the possibility to place a limit or market order. Imagine you want to get a share of Blueprint Medicines at 87.25, but its price is currently too prominent. With a limit order we will place the value at which we want to make the acquisition and until there are no shares selling at a certain price, the purchase operation of the share will not be executed. With a market order Degiro will buy the number of shares that we have indicated at the actual sale price, which would be very similar to the live listing price.

limit order interactive brokers Blueprint Medicines Corporation (BPMC)

In both cases it is essential that you look at the type of order: fixed or of the day . To give an example, in Spain, the stock market is in the morning until 1:00 p.m., and in the US it corresponds to the afternoon schedule in Spain. If the order is fixed, it will be kept until the point where it can be executed, but if you choose the “of the day” option, at the end of the day, if it has not been executed, it will be deleted from your section from Activity – Pending orders.

I hope this quick post will help you to invest in Blueprint Medicines. Thank you very much.

  Company information
  • Blueprint Medicines Corporation (BPMC) Address: 45 Sidney Street Cambridge, MA 02139-4133 United States 617374 7580 Website: http://www.blueprintmedicines.com
  • Ticker: BPMC
  • Sector: Sanitary
  • Industry: Biotechnology
  • Number of employees: 451
  • Listed market: Nasdaq
  • Value last year: 87.25$

company executives

Name Title Payment exercised Year of birth
Mr. Jeffrey W. Albers MBA, JD, MBA CEO, President and Director 1.2 million The 7.08M 1971
Mr. Alexis A. Borisy Co-Founder and Director 45k N/A 1972
Mr. Michael Landsittel CFO and Treasurer 585.5 thousand N/A 1972
Mrs Kathryn Haviland Director of operations 733.96k 1.84 million 1976
Dr Fouad Namouni R&D Pres 661.58k N/A 1969
Mrs. Tracey L. McCain Executive Vice President, Legal Director, Compliance Director and Sec. 716.83k N/A 1968
Mrs Ariel Hurley Chief Accountant, VP Fin. & Controller N/A N/A 1974
Dr. Christopher K. Murray Senior Vice President of Technical Operations N/A N/A 1963
Ms Kristin Hodous Mr. Mang. Investor Relations N/A N/A N/A
Mrs. Debra Durso-Bumpus Personnel director N/A N/A 1970

Recent Blueprint Medicines Events:

Recent Events July 14, 2020 Filed in Full 8-K: Entering into Material Definitive Agreement, Unrecorded Sale of Shares Jul 01, 2020 Filed in Full 8-K: Other Events, Financial Statements and Exhibits June 26, 2020 Filed in Full 8-K : Submission of matters to the vote of security holders June 08, 2020 Completely filed 8-K: Other events, financial statements and annexes May 29, 2020 Completely filed 8-K: Disclosure of Regulation FD, Other Events, Financial Statements and Annex